Atomoxetine for ADHD: Dosing, Contraindications, and Adverse Effects
Dosing Recommendations
Start atomoxetine at 0.5 mg/kg/day in children and adolescents up to 70 kg, titrate to a target of 1.2 mg/kg/day (maximum 1.4 mg/kg/day); for those over 70 kg and adults, start at 40 mg/day, target 80 mg/day (maximum 100 mg/day). 1
Pediatric Dosing Algorithm:
Children/adolescents ≤70 kg:
- Initial: 0.5 mg/kg/day
- Target: 1.2 mg/kg/day after minimum 3 days
- Maximum: 1.4 mg/kg/day
Children/adolescents >70 kg and adults:
- Initial: 40 mg/day
- Target: 80 mg/day after minimum 3 days
- Maximum: 100 mg/day
Critical Dosing Adjustments:
Reduce dose by 50% in patients taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine), those with moderate hepatic impairment, or known CYP2D6 poor metabolizers; reduce by 75% in severe hepatic impairment. 1 This is essential because poor metabolizers have 10-fold higher plasma concentrations and slower elimination 2.
Dosing Pitfalls:
Real-world data shows atomoxetine is frequently underdosed at approximately 60 mg/day in adults when 80 mg/day is the recommended target 3. Maintain patients at target dose for 4-6 weeks before judging efficacy 3. The 2026 dose-response meta-analysis demonstrates that doubling the atomoxetine dose approximately doubles the treatment effect in children and adolescents 4.
Atomoxetine can be given once daily (morning) or divided into two equal doses; once-daily dosing maintains efficacy into the evening 2.
Contraindications
Absolute Contraindications 1:
- Hypersensitivity to atomoxetine or product constituents
- MAOI use within 2 weeks (or other drugs affecting brain monoamine concentrations)
- Narrow-angle glaucoma
- Pheochromocytoma or history thereof
- Severe cardiovascular disorders that might deteriorate with clinically important increases in heart rate and blood pressure
Relative Contraindications/Cautions:
- Structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities: Atomoxetine generally should not be used in children/adolescents with these conditions; consider not using in adults with clinically significant cardiac abnormalities 1
- Hypertension, tachycardia, cardiovascular/cerebrovascular disease: Use with extreme caution 1
- Bipolar disorder: Screen patients before initiating treatment 5, 1
Common Adverse Effects
Children and Adolescents (≥5% and ≥2× placebo) 5, 1:
- Nausea (10% vs 5% placebo)
- Vomiting (11% vs 6% placebo)
- Fatigue (8% vs 3% placebo)
- Decreased appetite (16% vs 4% placebo)
- Abdominal pain (18% vs 10% placebo)
- Somnolence (11% vs 4% placebo)
Adults (≥5% and ≥2× placebo) 5:
- Constipation
- Dry mouth
- Nausea
- Fatigue
- Decreased appetite
- Dizziness
- Erectile dysfunction
- Urinary hesitation
Cardiovascular Effects:
Atomoxetine increases heart rate by 1-2 bpm and blood pressure by 1-4 mmHg on average 5. However, 5-10% of patients experience potentially clinically important changes (≥20 bpm heart rate increase or ≥15-20 mmHg blood pressure increase) 1. Monitor vital signs regularly.
Serious Adverse Effects:
BLACK BOX WARNING: Increased risk of suicidal ideation in children and adolescents 1. Monitor closely for suicidality, clinical worsening, and unusual behavioral changes, particularly when initiating treatment 5, 1.
- Severe liver injury: Discontinue immediately if jaundice or laboratory evidence of liver injury occurs; do not restart 1. Extremely rare but serious 2
- Growth effects: Initial height/weight delays in first 1-2 years, typically returns to expected trajectory after 2-3 years 5
- Priapism: Requires prompt medical attention 1
- Urinary retention/hesitancy: Monitor for effects on urine outflow 1
- Allergic reactions: Including anaphylaxis, angioedema, urticaria, rash 1
CYP2D6 Poor Metabolizer-Specific Effects:
Poor metabolizers (approximately 7% of Caucasians) experience higher rates of: insomnia (11% vs 6%), weight decrease (7% vs 4%), constipation (7% vs 4%), depression (7% vs 4%), tremor (5% vs 1%), and syncope (3% vs 1%) 1.
Discontinuation Rates:
In acute pediatric trials, 3% discontinued due to adverse events (vs 1.4% placebo); 6.3% of extensive metabolizers and 11.2% of poor metabolizers discontinued in all studies 1. The 2026 meta-analysis found maximum discontinuation risk of 3.6% at approximately 60 mg/day (vs 1.3% placebo), with no clear dose-dependent risk observed for atomoxetine 4.
Key Clinical Considerations
Obtain cardiac history (personal and family) before initiating treatment: Screen for sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome. If risk factors present, obtain ECG and consider cardiology referral 5.
Taper when discontinuing: Unlike stimulants, atomoxetine discontinuation is generally well tolerated with low incidence of discontinuation-emergent adverse events 2, but gradual tapering is prudent.
Efficacy timeline: The 2026 network meta-analysis confirms atomoxetine is significantly less effective than extended-release methylphenidate (OROS) and extended-release mixed amphetamine salts, but comparable to immediate-release methylphenidate 4, 2.
Advantages over stimulants: No abuse potential, not a controlled substance, useful for patients with comorbid anxiety, tics, or substance abuse risk 2, 6. Atomoxetine appears less likely than methylphenidate to exacerbate sleep disorders 2.